论文部分内容阅读
目的对ACI患者实施依达拉奉联合rt-PA治疗,分析其治疗效果和患者预后。方法选取62例发病6 h入院治疗ACI的患者,随机分为两组:治疗组和对照组。治疗组除常规治疗外,辅以依达拉奉联合rt-PA治疗,对照组仅采用rt-PA治疗。治疗后对患者进行ESS及BI评定。结果治疗组在实施治疗后7 d、14 d、21 d的ESS评分显著优于对照组,三个月后两组总有效率治疗组(85.2%),高于对照组(60.4%)。两组患者凝血功能、不良反应检查,无显著差异。结论对ACI患者采取依达拉奉联合rt-PA疗法快速、安全,对患者预后有积极作用。
Objective To investigate the therapeutic effect and prognosis of patients with ACI treated with edaravone combined with rt-PA. Methods Sixty-two patients admitted to hospital for ACI at 6 hours were randomly divided into two groups: treatment group and control group. In addition to conventional treatment, the treatment group was treated with edaravone combined with rt-PA and the control group with rt-PA alone. ESS and BI assessments were performed on patients after treatment. Results The ESS score of the treatment group at 7 d, 14 d and 21 d after treatment was significantly better than that of the control group. After three months, the total effective rate of the two groups was 85.2%, higher than that of the control group (60.4%). Two groups of patients with coagulation, adverse reactions, no significant difference. Conclusion The application of edaravone and rt-PA in patients with ACI is rapid and safe and has a positive effect on the prognosis of patients.